Page last updated: 2024-10-16

adenine and Leukemic Infiltration

adenine has been researched along with Leukemic Infiltration in 3 studies

Leukemic Infiltration: A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wanquet, A1
Birsen, R1
Bonnet, C1
Boubaya, M1
Choquet, S1
Dupuis, J1
Lepretre, S1
Re, D1
Fahri, J1
Michallet, AS1
Ysebaert, L1
Lemal, R1
Lamy, T1
Delarue, R1
Troussard, X1
Cymbalista, F1
Levy, V1
Dietrich, PY1
Leblond, V1
Aurran-Schleinitz, T1
Ponader, S1
Chen, SS1
Buggy, JJ1
Balakrishnan, K1
Gandhi, V1
Wierda, WG1
Keating, MJ1
O'Brien, S1
Chiorazzi, N1
Burger, JA1
Otová, B1
Sladká, M1
Blazek, K1
Schramlová, J1
Votruba, I1
Holý, A1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria.[NCT03868722]Phase 2/Phase 3212 participants (Anticipated)Interventional2019-10-11Recruiting
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236]Phase 127 participants (Actual)Interventional2015-06-18Active, not recruiting
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]Phase 322 participants (Actual)Interventional2019-12-09Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for adenine and Leukemic Infiltration

ArticleYear
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    British journal of haematology, 2017, Volume: 176, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Ner

2017
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Blood, 2012, Feb-02, Volume: 119, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Survival; Cells,

2012
Cytostatic effect of 9-(2-phosphonomethoxyethyl) adenine (PMEA). II. Lymphoblastic leukemia in Sprague-Dawley rats.
    Folia biologica, 1993, Volume: 39, Issue:3

    Topics: Adenine; Animals; Antineoplastic Agents; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Experimental; Le

1993